WuXi Biologics (Cayman) I... (WXIBF)
WuXi Biologics (Cayman) Statistics
Share Statistics
WuXi Biologics (Cayman) has 4.11B shares outstanding. The number of shares has increased by -1.11% in one year.
| Shares Outstanding | 4.11B |
| Shares Change (YoY) | -1.11% |
| Shares Change (QoQ) | 0.04% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 3.5B |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 32.25 and the forward PE ratio is null. WuXi Biologics (Cayman)'s PEG ratio is -1.37.
| PE Ratio | 32.25 |
| Forward PE | n/a |
| PS Ratio | 6.44 |
| Forward PS | n/a |
| PB Ratio | 2.72 |
| P/FCF Ratio | 250.76 |
| PEG Ratio | -1.37 |
Enterprise Valuation
WuXi Biologics (Cayman) has an Enterprise Value (EV) of 104.52B.
| EV / Sales | 6.14 |
| EV / EBITDA | 19 |
| EV / EBIT | 22.39 |
| EV / FCF | 239.07 |
Financial Position
The company has a current ratio of 2.78, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.78 |
| Quick Ratio | 2.54 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 0.83 |
| Debt / FCF | 10.43 |
| Interest Coverage | 24.92 |
Financial Efficiency
Return on Equity is 8.43% and Return on Invested Capital is 6.8%.
| Return on Equity | 8.43% |
| Return on Assets | 6.01% |
| Return on Invested Capital | 6.8% |
| Revenue Per Employee | $1.35M |
| Profits Per Employee | $270.36K |
| Employee Count | 12,575 |
| Asset Turnover | 0.3 |
| Inventory Turnover | 5.78 |
Taxes
| Income Tax | 603.18M |
| Effective Tax Rate | 14.45% |
Stock Price Statistics
The stock price has increased by 84.05% in the last 52 weeks. The beta is 0.68, so WuXi Biologics (Cayman)'s price volatility has been higher than the market average.
| Beta | 0.68 |
| 52-Week Price Change | 84.05% |
| 50-Day Moving Average | 3.07 |
| 200-Day Moving Average | 2.26 |
| Relative Strength Index (RSI) | 53.93 |
| Average Volume (20 Days) | 821 |
Income Statement
In the last 12 months, WuXi Biologics (Cayman) had revenue of 17.03B and earned 3.4B in profits. Earnings per share was 0.81.
| Revenue | 17.03B |
| Gross Profit | 6.83B |
| Operating Income | 3.95B |
| Net Income | 3.4B |
| EBITDA | 5.5B |
| EBIT | 4.33B |
| Earnings Per Share (EPS) | 0.81 |
Balance Sheet
The company has 9.67B in cash and 4.56B in debt, giving a net cash position of 5.11B.
| Cash & Cash Equivalents | 9.67B |
| Total Debt | 4.56B |
| Net Cash | 5.11B |
| Retained Earnings | 14.98B |
| Total Assets | 56.11B |
| Working Capital | 13.01B |
Cash Flow
In the last 12 months, operating cash flow was 4.67B and capital expenditures -4.23B, giving a free cash flow of 437.2M.
| Operating Cash Flow | 4.67B |
| Capital Expenditures | -4.23B |
| Free Cash Flow | 437.2M |
| FCF Per Share | 0.11 |
Margins
Gross margin is 40.08%, with operating and profit margins of 23.19% and 19.96%.
| Gross Margin | 40.08% |
| Operating Margin | 23.19% |
| Pretax Margin | 24.5% |
| Profit Margin | 19.96% |
| EBITDA Margin | 32.3% |
| EBIT Margin | 23.19% |
| FCF Margin | 2.57% |
Dividends & Yields
WXIBF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 3.1% |
| FCF Yield | 0.4% |
Analyst Forecast
Currently there are no analyst rating for WXIBF.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Dec 10, 2020. It was a forward split with a ratio of 3:1.
| Last Split Date | Dec 10, 2020 |
| Split Type | forward |
| Split Ratio | 3:1 |
Scores
| Altman Z-Score | 1.93 |
| Piotroski F-Score | 7 |